The UCSF HIV Clinical Trials Unit (CTU) will study treatment of HIV and its complications and prevention of HIV transmission in resource rich and poor settings through the ACTG and IMPAACT networks. This newly formed CTU creates a dynamic research agenda spanning pediatric to adult disease and features accomplished and innovative researchers, a cross-cutting research agenda, HIV infected clinic populations totaling 14,000, experienced clinical trials staff, strong mentoring programs and community participation. Dr. Havlir, chief of the HIV/AIDS Division at San Francisco General Hospital will direct the CTU and lead the adult UCSF Clinical Research Site (CRS) affiliated with ACTG;Dr. Wara will lead the pediatric, adolescent and pregnant women CRS, working through IMPAACT;Dr. Kamya will lead the adult CRS of Makerere University/Infectious Diseases Institute in Uganda, as a site for the ACTG. Our CTU contributions will occur in the NIH high priority research areas of optimization of clinical management and co-morbidities;translational research/drug development;prevention of mother to child transmission and vaccines. We will closely collaborate with the VTN/HPTN-affiliated San Francisco Department of Public Health prevention CTU in promoting a coordinated approach to prevention and treatment research in our community. Our goals:
Aim 1 : Design and conduct research to define simple, safe and lifelong antiretroviral treatment (ART) strategies for children and adults;new drugs and novel agents including vaccines for HIV and its complications;innovative approaches to treat HIV co-morbidities such as TB, malaria, HPV, hepatitis B and C, and studies of viral dynamics, reservoirs, and genomics to understand pharmacokinetics and treatment responses in HIV infected participants enrolled from CRS sites at UCSF and Makerere University.
Aim 2. Integrate the HIV treatment and prevention research agenda at the scientific, operational and community level by catalyzing scientific exchange, operations, and community outreach between prevention and treatment groups, testing novel strategies to prevent vertical and horizontal transmission.
Aim 3. Foster the development of the next generation of patient based researchers by mentoring junior investigators, leveraging support of existing funding training programs such as Fogarty and CFAR.
Aim 4. Conduct research with community-based input and outreach through vibrant community advisory boards and CTU support of community education and dissemination of research findings. The relevance of this research is that the studies will define new standards for the treatment of HIV disease and its complications and will improve ways to prevent transmission of HIV from mother to child. ADMINISTRATIVE COMPONENT:
|Petersen, Maya; Balzer, Laura; Kwarsiima, Dalsone et al. (2017) Association of Implementation of a Universal Testing and Treatment Intervention With HIV Diagnosis, Receipt of Antiretroviral Therapy, and Viral Suppression in East Africa. JAMA 317:2196-2206|
|Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111|
|Balzer, Laura B; Petersen, Maya L; van der Laan, Mark J et al. (2016) Targeted estimation and inference for the sample average treatment effect in trials with and without pair-matching. Stat Med 35:3717-32|
|Balzer, Laura B; van der Laan, Mark J; Petersen, Maya L et al. (2016) Adaptive pre-specification in randomized trials with and without pair-matching. Stat Med 35:4528-4545|
|Chamie, Gabriel; Clark, Tamara D; Kabami, Jane et al. (2016) A hybrid mobile approach for population-wide HIV testing in rural east Africa: an observational study. Lancet HIV 3:e111-9|
|Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68|
|Tenorio, Allan R; Chan, Ellen S; Bosch, Ronald J et al. (2015) Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286. J Infect Dis 211:780-90|
|Lehmann, David S; Ribaudo, Heather J; Daar, Eric S et al. (2015) Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics 25:51-9|
|Moore, Carrie B; Verma, Anurag; Pendergrass, Sarah et al. (2015) Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. Open Forum Infect Dis 2:ofu113|
|Wanga, Valentine; Venuto, Charles; Morse, Gene D et al. (2015) Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 25:450-61|
Showing the most recent 10 out of 49 publications